Table 3 Patient Characteristics
|  | Total population (n = 33) |
|---|---|
Age, years (median, IQR) | 58 (41–64) |
Male, [n (%)] | 20 (60.6) |
Race, [n (%)] | Â |
 Black/African American | 24 (72.7) |
 White | 9 (27.3) |
QTc ≥ 500 ms, [n (%)] | 4 (12.1) |
UDS on admit, [n (%)] | 22 (66.7) |
 Opiates | 22 (66.7) |
 Benzodiazepines | 6 (18.2) |
 Marijuana | 1 (3.0) |
 Cocaine | 8 (24.2) |
 Barbiturates | 1 (3.0) |
 Amphetamines | 2 (6.1) |
 Methadone | 6 (18.2) |
 Oxycodone | 3 (9.1) |
Required opioids 24Â h prior to microinduction, [n (%)] | 33 (100.0) |
 Median MME (median, IQR) | 30.8 (15–60) |
Admission day IV buprenorphine was started on [median (IQR)] | 4 (2–7) |
Time from last IV to first SL dose, hours [median (IQR)] | 10.3 (7.8–12.5) |
Day of microinduction transitioned to SL (median, IQR) | 4 (3–4) |
Methadone cross taper with buprenorphine, [n (%)] | 7 (21.2) |
 Last day of methadone dose (median, IQR) | 3 (2–4) |
 Required dose adjustment, [n (%)] | 8 (24.2) |
Completed buprenorphine induction therapy, [n (%)] | 30 (90.9) |
 Standard regimen, [n (%)] | 25 (92.6) |
 Slow regimen, [n (%)] | 5 (83.3) |
Discharge with buprenorphine prescription, [n (%)] | 30 (90.9) |
Buprenorphine only, [n (%)] | 19 (57.6) |
Buprenorphine with scheduled opioids, [n (%)] | 3 (9.1) |
Buprenorphine with as needed opioids, [n (%)] | 8 (24.2) |